Allakos Inc.

Quick facts

Phase 2 pipeline

• AK001 high dose · Immunology
  AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.
• AK001 low dose

Phase 1 pipeline

• AK001
• AK006 IV
• AK006-SC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Allakos Inc. portfolio CI brief
• Allakos Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies